Overview

GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
In this study, patients were randomly assigned to either receive fludarabine or not (20 mg/m2/d) in addition to induction chemotherapy, consolidation chemotherapy and the 3 subsequent re-induction courses during maintenance.
Phase:
Phase 3
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborators:
Novartis
Schering SA
Treatments:
Fludarabine
Fludarabine phosphate
Idarubicin
Vidarabine